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The aim was to investigate the effects of the GABAB receptor antagonist, CGP46381, on form-deprivation myopia (FDM) in guinea
pigs. Twenty-four guinea pigs had monocular visual deprivation induced using a diffuser for 11 days (day 14 to 25). The deprived
eyes were treated with daily subconjunctival injections (100𝜇l) of either 2% CGP46381, 0.2% CGP46381, or saline or received
no injection. The fellow eyes were left untreated. Another six animals received no treatment. At the start and end of the treatment
period, ocular refractions weremeasured using retinoscopy and vitreous chamber depth (VCD) and axial length (AL) using A-scan
ultrasound. All of the deprived eyes developed relative myopia (treated versus untreated eyes, 𝑃 < 0.05).The amount of myopia was
significantly affected by the drug treatment (one-way ANOVA, 𝑃 < 0.0001). The highest dose tested, 2% CGP46381, significantly
inhibited myopia development compared to saline (2% CGP46381: −1.08 ± 0.40D, saline: −4.33 ± 0.67D, 𝑃 < 0.01). The majority
of these effects were due to less AL (2% CGP46381: 0.03 ± 0.01mm, saline: 0.13 ± 0.02mm, 𝑃 < 0.01) and VCD (2% CGP46381:
0.02 ± 0.01mm, saline: 0.08 ± 0.01mm, 𝑃 < 0.01) elongation. The lower dose tested, 0.2% CGP46381, did not significantly inhibit
FDM (𝑃 > 0.05). Subconjunctival injections of CGP46381 inhibit FDM development in guinea pigs in a dose-dependent manner.
1. Introduction
Gamma-aminobutyric acid (GABA) is a major inhibitory
neurotransmitter within the eye and brain [1, 2]. There
are two main classes of GABA receptors: GABAA recep-
tors are ligand-gated ion channels (ionotropic receptors),
whereas GABAB receptors are G protein-coupled receptors
(metabotropic receptors) [3, 4]. GABAB receptors are com-
prised of two principal heterodimeric subunits, GABAB1 and
GABAB2. GABAB receptors via Gi/o proteins interact with
neuronal inwardly rectifying potassium and voltage-gated
calcium channels and when activated mediate slow synaptic
inhibition [5].
In eyes, GABAB receptors have been identified within the
retina on photoreceptors, bipolar cells, amacrine cells, and
ganglion cells [1, 6] and recently detected in chick retinal
pigment epithelium [7]. In the retina, GABAB receptors have
been shown tomodulate calcium currents in isolated goldfish
retinal ganglion cells [8], modify acetylcholine and glycine
release from amacrine cells in the rabbit retina [9], control
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arteriolar diameter in rat retinal whole-mounts [10], regulate
chick retinal calcium waves during retinal development [11],
and modify form-deprivation myopia (FDM) in chick eyes
[12]. Although usually considered an inhibitory transmitter,
the GABAB receptor agonist baclofen facilitates the L-type
calcium channel while inhibiting the N-type calcium current
in isolated spiking retinal neurons from salamander retina
[13].
CGP46381 is a water soluble GABAB receptor antagonist
of 219.26 molecular weight, IC
50
of 4.9 𝜇M [14]. GABAB
antagonists alter neuronal brain activity; for example, CGP
36742 and CGP 51176 exhibit antidepression like effects
in the forced swim test in mice [15] and SGS742 (CGP
36742) facilitates memory and cognition [16] in rats. The
GABAB antagonist CGP46381 is reported to antagonize
the diminishing response to repeated auditory stimuli in
rat hippocampus [17], inhibit suppression of hippocampal
long-term potentiation and impair spatial learning in rats
[18], stimulate spontaneous locomotor activity in mice [19],
modify the contrast of the sensory input map in the olfactory
receptor neuron terminals in mice [20], show proconvulsant
activity of cortical epileptic after discharges in developing
rat brain [21], and suppress absence seizures in the lethargic
mutant mouse and rat models [22, 23].
CGP46381 has been shown to inhibit FDM in the chick
model [12]. Other GABA antagonists shown to alter eye
growth in chick include GABAA (SR95531 [12], bicuculline
[24]) and GABAAOr (cis- and trans-3-ACPBPA [25] and
TPMPA [12, 24, 26]) receptor antagonists. Additional GABAB
receptor antagonists shown to inhibitmyopia in chick include
SCH50911 and 2OH-saclofen [12]. Among all the GABA
agents shown to inhibit myopia in chicks, cis- and trans-
3-ACPBPA, TPMPA, and CGP46381 are the most effective
[12, 25, 26]. Guinea pigs are a very useful mammalian eye
growth model [27–30]. The GABAAOr receptor antagonist
TPMPA has been reported to inhibit FDM in guinea pigs [31,
32]. The aim was to determine whether CGP46381 (GABAB
antagonist) inhibits FDM in guinea pigs.
2. Methods
2.1. Treatments: FDM and Subconjunctival Injections. Thirty
14-day-old pigmented guinea pigs (Cavia porcellus) were
obtained from Beijing Keyu Animal Centre (Beijing, China).
Animals were reared under a 12-hour light/12-hour dark cycle
(the light level was 1000 lux at the cage floor) in the animal
facility. All guinea pigs had free access to food and water, and
fresh cabbage was provided twice daily. Treatment and care
of animals were conducted according to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research.
Twenty-four guinea pigs had monocular visual depri-
vation induced using a diffuser (random application, using
velcro and tape, to the right or left eye) for 11 days (day 14
to 25) as previously described [29, 30, 33]. The deprived eyes
were treated with daily subconjunctival injections (100 𝜇L) of
either 2% CGP46381, 0.2% CGP46381, or saline or received
no injection (𝑛 = 6). The fellow eye was left untreated.
Another six animals received no treatment to either eye.
The concentration of CGP46381 was based on published
work involving the chick myopia model and the physico-
chemical characteristics of CGP46381. Stone and coauthors
[12] reported that intravitreal injection of CGP46381, at
doses ranging from 1 𝜇g to 200𝜇g, significantly inhibited the
development of FDM and the associated vitreous chamber
and axial elongation in chicks; the maximal antimyopia effect
occurred at doses above 100 𝜇g. Subconjunctival application
requires the injected agent to penetrate the sclera if it is to
have intraocular effects; Dong and coauthors [28] calculated
that only 1/104 of the applied dose reached the inside of the
guinea pig eye.Themaximumwater solubility of CGP46381 is
100mM(equivalent to 2.2%); to avoid solubility issues 2%was
chosen as the maximum concentration. Thus concentrations
of 0.2% (100 𝜇L contains 200𝜇g) and 2% were used.
CGP46381 (Tocris, Glasgow, UK) was dissolved in inject-
able saline and stored at −80∘C until required. Subconjunc-
tival injections were performed as previously described [28]
after removal of the diffuser. The injection was performed
under anaesthesia (2% isoflurane in oxygen; 26-gauge needle)
once daily (9–11 AM) in a timely manner (less than 2min)
for 11 days. The injection site was the peripheral bulbar
conjunctiva. After the injection, a drug bolus was observed
under the conjunctiva.Thediffuser was replaced immediately
following the injection.
2.2. Measurements: Refraction, Vitreous Chamber Depth, and
Axial Length. At the start and the end of the treatment
refraction and eye length measurements were made. Refrac-
tive errors were measured using streak retinoscopy in awake
animals following cycloplegia (3 drops of 1% cyclopento-
late hydrochloride; Alcon, Fort Worth, TX) as previously
described [28, 30]. Three readings were made along the
horizontal and vertical meridians and the average of these,
the spherical equivalent refraction (SER), used in subsequent
data analyses.
Axial length (AL) and vitreous chamber depth (VCD)
were measured using an A-scan ultrasonography (Suoer,
10MHz; Tianjin, China) under anaesthesia (2% isoflurane in
oxygen). The assumed conduction velocities were 1540m/s
[30]. The AL was defined as the distance between the front
of the cornea and the inner limiting membrane of the retina.
VCD was defined as the distance from the back of the lens
to the inner retinal surface. Three ultrasound measurements
comprising independent alignments of the probe were
averaged and used in data analysis.
2.3. Data Analysis. Data were analyzed using the GraphPad
Prism 5 (Version 5.01, GraphPad Software, Inc., USA). SER,
VCD, and AL of treated and untreated eyes of guinea pigs
within the same treatment group were analyzed using paired
𝑡-tests. The interocular differences in SER, AL, and VCD
of eyes of guinea pigs in different treatment groups were
analyzed using one-way ANOVA andDunnett’s post hoc test.
Both the within group and between group differences were
defined as significant at 𝑃 < 0.05.
3. Results
At commencement of the experiment there were no sig-
nificant differences in SER, AL, or VCD of treated and
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Figure 1: Effect of CGP46381 on spherical equivalent refraction
(SER). Interocular differences (mean ± SD) in SER varied signif-
icantly with treatment (𝑃 < 0.0001). Compared to saline, 2%
CGP46381 significantly inhibited themyopia (FDM+2%CGP46381
versus FDM + saline, 𝑃 < 0.01). The lower dose of CGP46381 0.2%
was not effective at inhibiting myopia (𝑃 > 0.05).
untreated eyes in each group (𝑃 > 0.05, paired 𝑡-test). There
were also no significant differences in SER, AL, or VCD of
eyes across different treatment groups (𝑃 > 0.05, one-way
ANOVA). Similarly at the end of the experiment, there were
no significant differences in SER, AL, or VCD of untreated
eyes across the groups (𝑃 > 0.05, one-way ANOVA).
At the end of the treatment period form-deprived eyes
had developed relative myopia (𝑃 < 0.05, paired 𝑡-test). The
interocular differences (treated minus untreated eye data) in
SER were −0.04 ± 0.17D in the normal group (neither eye
treated), −4.79 ± 0.60D in the FDMwith no injection group,
−4.33 ± 0.67D in the FDM + saline group, −3.92 ± 0.72D
in the FDM + 0.2% CGP46381 group, and −1.08 ± 0.40D in
the FDM + 2% CGP46381 group (Figure 1). The amount of
myopia induced was significantly affected by the drug treat-
ment (one-way ANOVA, 𝐹 = 74.61, 𝑃 < 0.0001). Myopia
was significantly less in the FDM+2%CGP46381 group com-
pared to that in FDM+ saline group (Dunnett’s post hoc, 𝑃 <
0.01). There was no significant difference in relative myopia
between the FDM + 0.2% CGP46381 group and the FDM +
saline group (Dunnett’s post hoc, 𝑃 > 0.05). These data show
that 2% CGP46381 subconjunctival injections inhibit FDM.
At the end of the treatment period the interocular
differences in AL were −0.00 ± 0.01mm in the normal group,
0.14 ± 0.02mm in the FDM with no injection group, 0.13 ±
0.02mm in the FDM + saline group, 0.11 ± 0.02mm in the
FDM + 0.2% CGP46381 group, and 0.03 ± 0.01mm in the
FDM + 2% CGP46381 group (Figure 2). The amount of AL
elongation was significantly affected by the drug treatment
(one-way ANOVA, 𝐹 = 58.38, 𝑃 < 0.0001). The amount of
AL elongation of the form-deprived eyes in the FDM + 2%
CGP46381 group was significantly less than that in FDM +
saline group (Dunnett’s post hoc, 𝑃 < 0.01). There was no
significant difference in AL elongation of form-deprived eyes
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Figure 2: Effect of CGP46381 on axial length (AL). Interocular
differences (mean ± SD) in AL varied significantly with treatment
(𝑃 < 0.0001). Compared to saline, 2% CGP46381 significantly
inhibited the AL elongation (FDM + 2% CGP46381 versus FDM +
saline,𝑃 < 0.01).The lower dose of CGP46381 0.2%was not effective
at inhibiting AL elongation (𝑃 > 0.05).
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Figure 3: Effect of CGP46381 on vitreous chamber depth (VCD).
Interocular differences (mean ± SD) in VCD varied significantly
with treatment (𝑃 < 0.0001). Compared to saline, 2% CGP46381
significantly inhibited the VCD elongation (FDM + 2% CGP46381
versus FDM + saline, 𝑃 < 0.01). The lower dose of CGP46381 0.2%
was not effective at inhibiting the VCD elongation (𝑃 > 0.05).
of the FDM + 0.2% CGP46381 and FDM + saline groups
(Dunnett’s post hoc: 0.2%CGP46381 versus saline, 𝑃 > 0.05).
At the end of treatment the interocular differences in
VCD were −0.00 ± 0.01mm in the normal group, 0.08 ±
0.02mm in the FDMwith no injection group, 0.08 ± 0.01mm
in the FDM + saline group, 0.07 ± 0.01mm in the FDM +
0.2% CGP46381 group, and 0.02 ± 0.01mm in FDM + 2%
CGP46381 group (Figure 3). The amount of VCD elongation
was significantly affected by the drug treatment (one-way
ANOVA, 𝐹 = 43.50, 𝑃 < 0.0001). The VCD elongation
in form-deprivation eyes in the FDM + 2% CGP46381
group was significantly reduced compared to the FDM +
saline group (one-way ANOVA and Dunnett’s test: 2%
CGP46381 versus saline, 𝑃 < 0.01). There was no significant
difference in VCD elongation in form-deprivation eyes of
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the FDM + 0.2% CGP46381 group and the FDM + saline
group (one-way ANOVA and Dunnett’s test: 0.2% CGP46381
versus saline, 𝑃 > 0.05). These data show that 2% CGP46381
subconjunctival injections inhibit the VCD elongation in
FDM (Figure 3).
4. Discussion
We found that CGP46381, a GABAB receptor antagonist,
which inhibits experimental myopia development in chick
models [12], also inhibits FDM in guinea pigs. Subconjunc-
tival injections of 2% CGP46381 significantly inhibited the
myopic shift and the elongation of AL and VCD. These data
show that CGP46381 not only inhibits FDM in an avian
model but also inhibits FDM in a mammalian (guinea pig)
model.
Stone and coauthors [12] reported that intravitreal injec-
tion of CGP46381 inhibited FDM in chicks; the minimum
effective dose was 1 𝜇g per day. Here we found that subcon-
junctival injection of CGP46381 inhibits FDM in guinea pigs;
the effective dose was 100 𝜇L of 2%CGP46381 (2mg per day),
whereas the lower dose, 100 𝜇L of 0.2% CGP46381 (200𝜇g
per day), did not inhibit myopia. These data show that the
effective antimyopia dose of CGP46381 applied via subcon-
junctival injection in guinea pigs is approximately 2000 times
higher than that for intravitreal injection in chicks.These data
are consistent with only 1/104 of the applied subconjunctival
dose reaching the vitreous chamber [26]. Leech and coau-
thors report that daily subconjunctival injections of piren-
zepine were significantly less effective at inhibiting myopia
than were intravitreal injections [34]. The concentration of
CGP46381 found here to inhibit myopia can now be used in
future investigations utilizing subconjunctival injections.
We previously reported that the GABAAOr receptor
antagonist TPMPA inhibits FDM in guinea pigs [32] and here
we report that the GABAB receptor antagonist CGP46381
has similar antimyopia effects. The maximal doses tested in
both cases were similarly effective: 2% CGP46381 (91mM)
inhibited ∼70% of the FDM and 1% TPMPA (62mM)
inhibited ∼80% (𝑃 = 0.493).The effects of 2% CGP46381 and
1% TPMPA on the AL and VCD elongation were also similar
(𝑃 = 0.200 and 𝑃 = 0.243, resp.). The lower dose tested,
0.2% CGP46381 (9mM), did not inhibit FDM whereas 0.3%
TPMPA (19mM) inhibited ∼30%. The 0.3% dose of TPMPA
was more effective than 0.2% CGP46381 at inhibiting myopia
(𝑃 = 0.047) and VCD elongation (𝑃 = 0.012), while the
degree of AL elongation was similar (𝑃 = 0.066). Stone and
coauthors [12] reported that the minimum dose for TPMPA
inhibiting FDM in chicks is 0.1𝜇g and 1 𝜇g for CGP46381, and
when a higher dose was used (e.g., 100 ug), the antimyopia
effects for TPMPA and CGP46381 were similar. Our results
in guinea pigs show correspondence to the results in chicks.
In this study, we found that CGP46381 inhibits FDM in
guinea pigs, but the potential targets and possible mecha-
nisms are not clear. GABAB receptors have been detected in
the retina [1] andRPE [7], which suggested that the retina and
RPE would be the potential targets for CGP46381 inhibiting
myopia. Sclera [35], choroid [36], RPE [37], and retina [38]
are all implicated in myopia development, and the sclera
determines the ocular size. How CGP46381 contacts with the
GABAB receptors in the retina and RPE and how the signals
are then translated to the sclera to inhibit the eye elongation
and myopia development require further investigation.
Several other kinds of neurotransmitter agents inhibit
experimentalmyopia in a variety of animalmodels, including
the muscarinic acetylcholine receptor nonspecific antagonist
atropine (in chicks [39], mice [40], and monkeys [41]), the
M1 receptor antagonist pirenzepine (in chicks [34], guinea
pigs [27], and monkeys [41]), the M4 muscarinic antagonist
MT-3 (in chicks [42] and tree shrews [43]), the dopamine
receptor agonist, and apomorphine (in chicks [33, 44], guinea
pigs [28], and monkeys [45]). Thus GABA must be involved
in a complicated eye growth pathway involving many retinal
cells and associated transmitters.
In summary, we found that subconjunctival injection of
the GABAB receptor antagonist CGP46381 can effectively
inhibit FDM in guinea pigs. Whether CGP46381 inhibits
myopia in the other animal models and humans requires
further investigation. The potential targets and possible
mechanisms via which CGP46381 inhibits myopia remain
unexplored.
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